106 related articles for article (PubMed ID: 29444511)
1. Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI.
Kieler M; Müllauer L; Koperek O; Bianconi D; Unseld M; Raderer M; Prager GW
Oncology; 2018; 94(5):306-310. PubMed ID: 29444511
[TBL] [Abstract][Full Text] [Related]
2. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Gay L; Presta MJ; Sheehan CE; Ali SM; Elvin JA; Labrecque E; Hiemstra C; Buell J; Otto GA; Yelensky R; Lipson D; Morosini D; Chmielecki J; Miller VA; Stephens PJ
J Clin Pathol; 2014 Nov; 67(11):968-73. PubMed ID: 25078331
[TBL] [Abstract][Full Text] [Related]
4. Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis.
Papathomas TG; Duregon E; Korpershoek E; Restuccia DF; van Marion R; Cappellesso R; Sturm N; Rossi G; Coli A; Zucchini N; Stoop H; Oosterhuis W; Ventura L; Volante M; Fassina A; Dinjens WN; Papotti M; de Krijger RR
Hum Pathol; 2016 Dec; 58():113-122. PubMed ID: 27589897
[TBL] [Abstract][Full Text] [Related]
5. Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas.
Ragazzon B; Libé R; Assié G; Tissier F; Barreau O; Houdayer C; Perlemoine K; Audebourg A; Clauser E; René-Corail F; Bertagna X; Dousset B; Bertherat J; Groussin L
Eur J Endocrinol; 2014 Mar; 170(3):385-91. PubMed ID: 24347427
[TBL] [Abstract][Full Text] [Related]
6. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
Gaujoux S; Pinson S; Gimenez-Roqueplo AP; Amar L; Ragazzon B; Launay P; Meatchi T; Libé R; Bertagna X; Audebourg A; Zucman-Rossi J; Tissier F; Bertherat J
Clin Cancer Res; 2010 Nov; 16(21):5133-41. PubMed ID: 20978149
[TBL] [Abstract][Full Text] [Related]
9. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
10. β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma.
Gaujoux S; Grabar S; Fassnacht M; Ragazzon B; Launay P; Libé R; Chokri I; Audebourg A; Royer B; Sbiera S; Vacher-Lavenu MC; Dousset B; Bertagna X; Allolio B; Bertherat J; Tissier F
Clin Cancer Res; 2011 Jan; 17(2):328-36. PubMed ID: 21088256
[TBL] [Abstract][Full Text] [Related]
11. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
[TBL] [Abstract][Full Text] [Related]
12. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.
Juhlin CC; Goh G; Healy JM; Fonseca AL; Scholl UI; Stenman A; Kunstman JW; Brown TC; Overton JD; Mane SM; Nelson-Williams C; Bäckdahl M; Suttorp AC; Haase M; Choi M; Schlessinger J; Rimm DL; Höög A; Prasad ML; Korah R; Larsson C; Lifton RP; Carling T
J Clin Endocrinol Metab; 2015 Mar; 100(3):E493-502. PubMed ID: 25490274
[TBL] [Abstract][Full Text] [Related]
13. Molecular genomic profiling of adrenocortical cancers in clinical practice.
Darabi S; Braxton DR; Eisenberg BL; Demeure MJ
Surgery; 2021 Jan; 169(1):138-144. PubMed ID: 32709489
[TBL] [Abstract][Full Text] [Related]
14. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
[TBL] [Abstract][Full Text] [Related]
15. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
16. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer.
De Martino MC; Al Ghuzlan A; Aubert S; Assié G; Scoazec JY; Leboulleux S; Do Cao C; Libè R; Nozières C; Lombès M; Pattou F; Borson-Chazot F; Hescot S; Mazoyer C; Young J; Borget I; Colao A; Pivonello R; Soria JC; Bertherat J; Schlumberger M; Lacroix L; Baudin E
J Clin Endocrinol Metab; 2013 Oct; 98(10):4080-8. PubMed ID: 23979958
[TBL] [Abstract][Full Text] [Related]
17. Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques--the Usefulness in the Qualification of Cancer Patients for Molecularly-Targeted Therapies.
Nicoś M; Wojas-Krawczyk K; Krawczyk P; Milanowski J
Adv Clin Exp Med; 2015; 24(4):715-23. PubMed ID: 26469118
[TBL] [Abstract][Full Text] [Related]
18. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
[TBL] [Abstract][Full Text] [Related]
19. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
20. Applied precision cancer medicine in metastatic biliary tract cancer.
Taghizadeh H; Müllauer L; Mader R; Prager GW
Hepatol Int; 2020 Mar; 14(2):288-295. PubMed ID: 32100259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]